Ocugen, Inc. (NASDAQ:OCGN) Shares Acquired by GSA Capital Partners LLP

GSA Capital Partners LLP grew its holdings in Ocugen, Inc. (NASDAQ:OCGN) by 43.0% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,638,033 shares of the company’s stock after purchasing an additional 492,300 shares during the period. GSA Capital Partners LLP’s holdings in Ocugen were worth $1,157,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also modified their holdings of the business. XTX Topco Ltd lifted its stake in shares of Ocugen by 8.5% in the 4th quarter. XTX Topco Ltd now owns 254,995 shares of the company’s stock valued at $205,000 after purchasing an additional 19,894 shares during the last quarter. Rhumbline Advisers raised its holdings in shares of Ocugen by 6.4% in the 1st quarter. Rhumbline Advisers now owns 345,130 shares of the company’s stock valued at $244,000 after buying an additional 20,655 shares during the period. Two Sigma Securities LLC raised its holdings in shares of Ocugen by 92.9% in the 4th quarter. Two Sigma Securities LLC now owns 51,909 shares of the company’s stock valued at $42,000 after buying an additional 25,004 shares during the period. Tower Research Capital LLC TRC raised its holdings in shares of Ocugen by 309.6% in the 4th quarter. Tower Research Capital LLC TRC now owns 39,848 shares of the company’s stock valued at $32,000 after buying an additional 30,120 shares during the period. Finally, ProShare Advisors LLC raised its holdings in shares of Ocugen by 66.7% in the 4th quarter. ProShare Advisors LLC now owns 80,613 shares of the company’s stock valued at $65,000 after buying an additional 32,262 shares during the period. Institutional investors and hedge funds own 10.27% of the company’s stock.

Ocugen Price Performance

Shares of NASDAQ OCGN opened at $1.07 on Thursday. The company has a debt-to-equity ratio of 1.74, a current ratio of 2.60 and a quick ratio of 2.60. The company has a market cap of $312.47 million, a price-to-earnings ratio of -5.63 and a beta of 4.18. The stock’s 50-day moving average is $1.02 and its two-hundred day moving average is $0.80. Ocugen, Inc. has a 1-year low of $0.52 and a 1-year high of $1.50.

Ocugen (NASDAQ:OCGN) last posted its quarterly earnings results on Friday, May 9th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01. The company had revenue of $1.48 million for the quarter. Ocugen had a negative return on equity of 223.00% and a negative net margin of 1,271.12%. Analysts forecast that Ocugen, Inc. will post -0.2 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

OCGN has been the topic of several research analyst reports. HC Wainwright reiterated a “buy” rating and issued a $7.00 price objective on shares of Ocugen in a report on Tuesday, June 24th. Chardan Capital reiterated a “buy” rating and issued a $7.00 price objective on shares of Ocugen in a report on Tuesday, June 24th.

About Ocugen

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.